Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics

Acute Febrile Illnesses Clinical Trial

Official title:

Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics in Africa and Latin America

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03047642
• Other study ID #: AFI_01
• Status: Completed
• Start date: April 27, 2017
• Est. completion date: November 27, 2019

Study information

• Verified date: February 2021
• Source: Foundation for Innovative New Diagnostics, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This project aims to evaluate the performance characteristics of rapid tests to differentiate bacterial from non-bacterial infection in febrile adults and children presenting at OPDs (outpatient departments) i.e.("fever triage assays") in three LMICs. The evaluation will include a different commercial biomarker combinations as well as individual biomarkers to assess their individual or combined value in the target population. Markers will be evaluated onsite in ELISA or RDT format, as appropriate. Further, this study aims to contribute to a centralized biobank of well-characterized specimens for use by IVD companies and academic institutions for the development and evaluation of emerging assays.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2000
• Est. completion date: November 27, 2019
• Est. primary completion date: October 27, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 65 Years

Eligibility

Inclusion Criteria:

Any non-severely ill subject presenting with acute fever defined as: temperature of more than 38°C at initial evaluation of less than 7 days of symptoms at presentation.

Inclusion criteria:

• Children 2-17 years of age
• Adults 18-65 years of age
• Signed written informed consent for study participation. For recruitment purposes, subjects will be classified into two groups, children and adults. For children, age >2 years is the minimum cut-off, based on the amount of blood volume to be obtained in the study. WHO guidelines for allowable blood volume in 24 hours recommend that no more than 1-5% of total blood volume (75-80 ml/kg for older children) be obtained. Applying the average weight of a 2 year old toddler =12 kg, the allowable blood volume to be drawn in 24 hours at 1-5% of the total blood volume is 9.6 - 48 mL . For minors, caregivers will provide informed consent. Documented assent for children of 12 to 16 years of age will be required for their participation.

Exclusion Criteria:

• Subjects who are felt to be in critical condition (based on clinician assessment or the presence of any general signs of critical illness as defined by WHO guidelines (for children: extensive vomiting, active seizure or recent history of seizures, altered mentation, inability to feed, or any of the severe IMNCI classifications; for adults: impending airway obstruction, central cyanosis, severe respiratory distress, feeble pulse, active seizure or recent history of seizures, or unconsciousness) because the target population for the study is non-severe febrile subjects.
• Subjects can only be enrolled once into the study.

Related Conditions & MeSH terms

• Acute Febrile Illnesses
• Fever

Intervention

Diagnostic Test:
• Biomarker assay
There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients

Locations

Country	Name	City	State
Brazil	Instituto Nacional de Infectologia Evandro Chagas - Fiocruz (INIEC)	Rio de Janeiro
Gabon	CERMEL	Lambaréné
Malawi	Karonga Prevention Study	Chilumba	Karonga District

Sponsors (4)

Lead Sponsor	Collaborator
Foundation for Innovative New Diagnostics, Switzerland	Centre de Recherche Médicale de Lambaréné, Instituto Nacional de Infectologia Evandro Chagas, Malawi Epidemiology and Intervention Research Unit

Countries where clinical trial is conducted

Brazil,  Gabon,  Malawi, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic sensitivity and specificity to determine bacterial infections compared to clinical and microbiological results aggregated in a study database.	Microbiological testing (blood culture positive/negative, malaria pos/neg, S. Tyhpi RDT pos/neg) and clinical assessments of symptoms (respiratory, gastro, no foci) will be recorded and reviewed by a clinical panel upon completion of the study to assign a final category (bacterial or non-bacterial). These categories are used in the evaluation of the biomarker assays to evaluate their performance in differentiating bacterial from non-bacterial infections. Where applicable, the same categories will be used to determine the area under the curve by employing receiver operator characteristics (ROC) analysis of quantitative markers.	1year